Innovent, Eli Lilly cite a new success for their PD-1 in lung cancer, with a likely pioneering approval in China looming
Here come the made-in-China checkpoints.
Innovent, one of the most prominent operations in the new wave of Chinese biotechs that have been going global recently, has plucked out data from a single cohort of 20 patients to underscore the promise of their PD-1 drug sintilimab.
Innovent isn’t the only Chinese biotech to work on the country’s first wave of locally developed checkpoints. Hengrui has one, initially allied to Incyte, which moved on to another partner after some troubling rashes appeared in patients. And BeiGene along with Shanghai Junshi are all angling for their first China approvals in H1 of next year.
A check of the database at PharmCube in Shanghai revealed 68 different PD-1/L1 drugs in China’s pipeline, part of the tsunami of checkpoints that has been forming in Asia. Endpoints’ Amber Tong assembled the full list, which you can see below.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.